Casi Pharmaceuticals, Inc.
SEC CIK 1962738 · CASIF · last insider filing 2026-04-23
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Folinsbee Thomas | Director | filed 2026 - 2026 |
| Zeng Xuebo | Director | filed 2026 - 2026 |
| Krebs-Pohl Barbara Helene Hannelore | Director | filed 2026 - 2026 |
| Wu Alex | Director | filed 2026 - 2026 |
| He Wei-Wu | Director | filed 2026 - 2026 |
| Huang James | Director | filed 2026 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Gao Wei R | General Counsel | filed 2026 - 2026 |
| Qian Kun | Global Controller | filed 2026 - 2026 |
| Huang Hai | Global Chief Commercial Ofcr | filed 2026 - 2026 |
| Zukiwski Alexander A | Global Chief Medical Officer | filed 2026 - 2026 |
| Wang Chunhua | Chief Operating Officer | filed 2026 - 2026 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.